Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
NEOVASC INC (NVCN) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/31/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Annual Information Form for the year ended December 31, 2022",
"Audited Consolidated Financial Statements for the years ended December 31, 2022, 2021 and 2020, prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board, including the report of the auditors thereon",
"Management’ s Discussion and Analysis of Financial Condition and Result of Operations for the years ended December 31, 2022, 2021 and 2020",
"Consent of Grant Thornton LLP (US)",
"Consent of Grant Thornton LLP (Canada)"
03/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Final Order"
02/10/2023 6-K Quarterly results
02/01/2023 6-K Quarterly results
01/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Notice of the Meeting and Record Date"
01/18/2023 6-K Quarterly results
01/17/2023 6-K Quarterly results
01/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"VANCOUVER, BC"
11/28/2022 6-K Quarterly results
11/18/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
Docs: "FORM 6-K",
"Unaudited Condensed Interim Consolidated Financial Statements for the period ended September 30, 2022",
"Management’s Discussion and Analysis for the period ended September 30, 2022",
"Form 52-109F2 - Certification of Interim Filings - Full Certificate - CEO",
"Form 52-109F2 - Certification of Interim Filings - Full Certificate - CFO",
"Neovasc Announces Third Quarter Financial Results and Provides Corporate Update VANCOUVER and MINNEAPOLIS - - Nov 10, 2022 - Neovasc Inc. today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Generated revenues of $923,000, a quarterly record and a year-over-year increase of 31% compared to the third quarter of 2021. Accelerating acceptance of Reducer in the UK and French markets, with France the largest volume market in the quarter. Continued enrollment in the COSIRA II pivotal trial, with enrollment expected to be complete in the first half of 2024 and initial data readout in the second half of 2024. In July, 2022, the Company received approval to expand the scope of the COSIRA II trial with a registry to include patients suffering from angin..."
11/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"About Reducer"
10/27/2022 6-K Quarterly results
09/20/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc Provides Update on Mitral Valve Program After careful analysis and given the emerging opportunities for the Reducer in the ANOCA patient population, the Company has decided to put further development and the European CE-Marking regulatory approval process for the Tiara-TA on hold and focus the organization on Reducer therapy and the ongoing COSIRA-II clinical trial. Strategically, the Company believes this is the best use of its financial and workforce resources. The increased complexity, cost, and ever-increasing regulatory hurdles developed over the last several years with respect to standards and requirements, and in the new European MDR regulations, were meaningful factors in the company's analysis. The Company will continue work on its mitral and tricuspid valve intellectual p..."
09/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"About Reducer The Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies. Reducer is investigational in the United States in the COSIRA-II clinical trial. Refractory angina, resulting in continued symptoms despite maximal medical therapy and without revascularization options, affects millions of patients worldwide, who typically lead severely restricted lives because of their disabling symptoms. The Reducer is designed to alter blood flow within the myocardium of the heart and increase the perfusion of oxygenated blood to ischemic areas of the heart muscl..."
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"New Investigational Data to be Presented On Monday, September 19, 2022, Shmuel Banai, MD, Tel Aviv Medical Center, will present new early data on the use of the Neovasc Reducer™ in a patient population suffering from angina with non-obstructive coronary artery disease . The international investigational data will be featured in the "TCT Innovation" session scheduled from 11:00 AM - 12:30 PM EDT in the Innovation Theater, Room 210, Level 2, Boston Convention and Exhibition Center. The presentation entitled, "Coronary Sinus Reduction for the Treatment of Symptomatic Microvascular Coronary Disease: Early Clinical Results" is the first time the Company will highlight data on the impact of the Reducer on the objective measurement of coronary flow reserve in patients that have chest pain w..."
08/30/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc to Participate in H.C. Wainwright 24 th Annual Global Investment Conference VANCOUVER and MINNEAPOLIS - - August 30, 2022 - Neovasc, Inc. today announced that its management team will be participating in the H.C. Wainwright 24 th Annual Global Investment Conference to be held September 12-14, 2022, in New York City. Neovasc's President and Chief Executive Officer, Fred Colen, will be presenting at 1:30 pm ET on Tuesday, September 13, 2022. A live webcast of the presentation can be accessed using the link here . Additionally, a recording of the presentation will be available in the Investors section of the Neovasc website at Presentations & Events , and will be archived for 90 days. Neovasc is a specialty medical device company that develops, manufactures, and markets products for ..."
08/11/2022 6-K Quarterly results
07/28/2022 6-K Quarterly results
07/26/2022 6-K Quarterly results
07/05/2022 6-K Quarterly results
06/08/2022 6-K Quarterly results
05/23/2022 6-K Quarterly results
05/16/2022 6-K Quarterly results
05/12/2022 6-K Quarterly results
05/12/2022 6-K Quarterly results
04/29/2022 6-K Quarterly results
04/28/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc Comments on European Heart Journal Publication"
04/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc Announces Effective Date of Share Consolidation VANCOUVER, BC – April 27, 2022 -- Neovasc Inc. , a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that the Company has filed articles of amendment, effective today, to effect the previously announced share consolidation of its issued and outstanding common shares on the basis of one post-Consolidation Common Share for every twenty-five pre-Consolidation Common Shares. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 68,228,061 Common Shares to approximately 2,729,107 Common Shares. The Common Shares are expected to commence..."
04/27/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"VANCOUVER, BC"
04/20/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference VANCOUVER and MINNEAPOLIS via NewMediaWire -- Neovasc, Inc. today announced that its management team will be participating in the 2022 Bloom Burton & Co. Healthcare Investment Conference to be held May 2-3, 2022. Fred Colen, Neovasc's Chief Executive Officer, will be presenting at 4:00 pm ET on Monday, May 2. The presentation can be accessed here . Additionally, a recording of the presentation will be available on the conference website, and will be archived for 90 days. Neovasc is a specialty medical device company that develops, manufactures, and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is under clinical inv..."
04/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
04/13/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"NEOVASC INC. REPORTS RESULTS OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS Vancouver, BC, Canada - April 13, 2022 - Neovasc Inc. is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on April 12, 2022 in Vancouver, B.C. . At the Meeting, the shareholders of the Company re-elected board members Steven Rubin, Paul Geyer, Doug Janzen, Norman Radow, Alexei Marko and Fred Colen to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows: Nominee Votes For % Votes For Votes Withheld % Votes Withheld Steven Rubin 8,055,190 97.73% 187,258 2.27% Paul Geyer 8,070,556 97.91% 171,892 2..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy